<p>Harbor Capital Advisors Inc. 在最近向美國證券交易委員會（SEC）提交的文件中表示，其在 MiMedx Group, Inc (NASDAQ:MDXG - 免費報告) 的持股在第三季度減少了 71.3%。該機構投資者在此期間出售了 833,432 股後，持有該公司 335,763 股股票。截至其最近的 SEC 文件，Harbor Capital Advisors Inc. 持有的 MiMedx Group 股票約佔 0.23%，價值 2,344,000 美元。</p>
<p>其他幾家對沖基金也最近調整了對該公司的持股。CWM LLC 在第二季度將其在 MiMedx Group 的持股增加了 63.8%。CWM LLC 目前持有該公司 4,857 股股票，價值 30,000 美元，此前在上個季度又增持了 1,892 股。Rhumbline Advisers 在第一季度將其在 MiMedx Group 的持股增加了 1.4%。Rhumbline Advisers 目前持有該公司 177,156 股股票，價值 1,346,000 美元，此前在上個季度又購買了 2,436 股。SkyView Investment Advisors LLC 在第二季度將其在 MiMedx Group 的持股增加了 3.6%。SkyView Investment Advisors LLC 目前持有該公司 87,734 股股票，價值 523,000 美元，此前在此期間又增持了 3,032 股。新澤西州警察和消防員退休系統在第二季度將其在 MiMedx Group 的持股增加了 14.9%。新澤西州警察和消防員退休系統目前持有該公司 28,135 股股票，價值 172,000 美元，此前在此期間又增持了 3,642 股。最後，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度將其在 MiMedx Group 的持股增加了 5.8%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前持有該公司 73,518 股股票，價值 559,000 美元，此前在上個季度又增持了 4,049 股。機構投資者持有該公司 79.15% 的股票。</p>
<h2>MiMedx Group 的內部活動</h2>
<p>在相關消息中，內部人士 Kimberly Maersk-Moller 於 11 月 6 日星期四出售了 58,300 股該公司的股票。股票以平均價格 7.42 美元出售，總交易額為 432,586.00 美元。出售後，該內部人士直接持有該公司 236,982 股股票，價值約 1,758,406.44 美元。這代表其持股減少了 19.74%。該交易在向 SEC 提交的文件中披露，相關文件可通過此超鏈接訪問。內部人士持有該公司 1.70% 的股票。</p>
<h2>MiMedx Group 股價上漲 1.1%</h2>
<p>MDXG 的股票在星期五開盤價為 7.08 美元。該公司的 50 日移動平均線為 7.05 美元，200 日移動平均線為 6.88 美元。MiMedx Group, Inc 的 52 周低點為 5.79 美元，52 周高點為 9.71 美元。該公司的市值為 10.5 億美元，市盈率為 26.20，貝塔係數為 1.64。該公司的債務與股本比率為 0.07，速動比率為 3.95，流動比率為 4.41。</p>
<p>MiMedx Group (NASDAQ:MDXG - 獲取免費報告) 最近於 11 月 13 日星期一發布了季度財報。該公司報告本季度每股收益為（0.03）美元。該公司的季度收入為 67.69 百萬美元。MiMedx Group 的淨利潤率為 10.38%，股本回報率為 27.19%。作為一個整體，研究分析師預測 MiMedx Group, Inc 本年度將發佈 0.3 的每股收益。</p>
<h2>分析師評級調整</h2>
<p>一些股票分析師最近對該股票進行了評估。華爾街 Zen 在 11 月 2 日星期日的報告中將 MiMedx Group 的股票評級從 “買入” 上調至 “強力買入”。瑞穗證券在 12 月 17 日的研究報告中將 MiMedx Group 的股票目標價從 12.00 美元下調至 10.00 美元，並對該股票給予 “跑贏大盤” 的評級。最後，Weiss Ratings 在週一的研究報告中重新發布了對 MiMedx Group 股票的 “持有（c）” 評級。兩位投資分析師對該股票給予了買入評級，一位給予了持有評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，共識目標價為 11.00 美元。</p>
<p><strong>獲取我們關於 MDXG 的最新報告</strong></p>
<h2>MiMedx Group 公司簡介</h2>
<p>（免費報告）</p>
<p>MiMedx Group, Inc 是一家生物製藥公司，專注於開發、製造和營銷源自人類胎盤組織的再生生物材料產品。該公司的核心使命是利用羊膜和絨毛膜中的細胞外基質和生長因子來支持傷口癒合和外科應用。MiMedx 的產品線利用專有的淨化工藝，旨在保留原生組織特性，同時確保無菌和安全。</p>
<p>MiMedx 的主要產品包括以 EpiFix® 和 AmnioFix® 等名稱品牌的羊膜/絨毛膜同種異體移植物，適用於急性和慢性傷口的治療，包括糖尿病足潰瘍、靜脈性腿部潰瘍和手術部位修復。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們更看好的股票，勝過 MiMedx Group</li>
<li>將你的 “死錢” 轉變為每月 306 美元以上（從這個月開始）</li>
<li>華盛頓準備開戰</li>
<li>在 1 月 1 日之前將 1,000 美元投入這隻股票 [不是 NVDA]</li>
<li>麥當勞的秘密</li>
<li>來自奇怪的新 “AI 燃料” 的 33,000% 繁榮？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 MiMedx Group 嗎？</h2>
<p>在考慮 MiMedx Group 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買... 而 MiMedx Group 並不在名單上。</p>
<p>雖然 MiMedx Group 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

MDXG

<p>Harbor Capital Advisors Inc. 在第三季度減少了對 MiMedx Group, Inc 的持股，降幅為 71.3%，目前持有 335,763 股。其他對沖基金也調整了他們的持股。MiMedx Group 的股票上漲 1.1%，市值為 10.5 億美元。分析師對該股票給予了 “適度買入” 的共識評級，目標價格為 11.00 美元</p>

<p>Harbor Capital Advisors Inc. trimmed its position in MiMedx Group, Inc (NASDAQ:MDXG - Free Report) by 71.3% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 335,763 shares of the company's stock after selling 833,432 shares during the period. Harbor Capital Advisors Inc. owned about 0.23% of MiMedx Group worth $2,344,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Harbor Capital Advisors Inc. 在最近向美國證券交易委員會（SEC）提交的文件中表示，其在 MiMedx Group, Inc (NASDAQ:MDXG - 免費報告) 的持股在第三季度減少了 71.3%。該機構投資者在此期間出售了 833,432 股後，持有該公司 335,763 股股票。截至其最近的 SEC 文件，Harbor Capital Advisors Inc. 持有的 MiMedx Group 股票約佔 0.23%，價值 2,344,000 美元。</p>
</div><p>Several other hedge funds have also recently modified their holdings of the company. CWM LLC grew its holdings in shares of MiMedx Group by 63.8% in the second quarter. CWM LLC now owns 4,857 shares of the company's stock valued at $30,000 after acquiring an additional 1,892 shares in the last quarter. Rhumbline Advisers boosted its position in MiMedx Group by 1.4% in the first quarter. Rhumbline Advisers now owns 177,156 shares of the company's stock worth $1,346,000 after purchasing an additional 2,436 shares during the last quarter. SkyView Investment Advisors LLC grew its stake in MiMedx Group by 3.6% in the 2nd quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company's stock valued at $523,000 after purchasing an additional 3,032 shares during the period. Police &amp; Firemen s Retirement System of New Jersey grew its stake in MiMedx Group by 14.9% in the 2nd quarter. Police &amp; Firemen s Retirement System of New Jersey now owns 28,135 shares of the company's stock valued at $172,000 after purchasing an additional 3,642 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of MiMedx Group by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company's stock valued at $559,000 after purchasing an additional 4,049 shares during the last quarter. Institutional investors own 79.15% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家對沖基金也最近調整了對該公司的持股。CWM LLC 在第二季度將其在 MiMedx Group 的持股增加了 63.8%。CWM LLC 目前持有該公司 4,857 股股票，價值 30,000 美元，此前在上個季度又增持了 1,892 股。Rhumbline Advisers 在第一季度將其在 MiMedx Group 的持股增加了 1.4%。Rhumbline Advisers 目前持有該公司 177,156 股股票，價值 1,346,000 美元，此前在上個季度又購買了 2,436 股。SkyView Investment Advisors LLC 在第二季度將其在 MiMedx Group 的持股增加了 3.6%。SkyView Investment Advisors LLC 目前持有該公司 87,734 股股票，價值 523,000 美元，此前在此期間又增持了 3,032 股。新澤西州警察和消防員退休系統在第二季度將其在 MiMedx Group 的持股增加了 14.9%。新澤西州警察和消防員退休系統目前持有該公司 28,135 股股票，價值 172,000 美元，此前在此期間又增持了 3,642 股。最後，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度將其在 MiMedx Group 的持股增加了 5.8%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前持有該公司 73,518 股股票，價值 559,000 美元，此前在上個季度又增持了 4,049 股。機構投資者持有該公司 79.15% 的股票。</p>
</div><h2>Insider Activity at MiMedx Group</h2>
<div class="lb-trans"><h2>MiMedx Group 的內部活動</h2>
</div><p>In related news, insider Kimberly Maersk-Moller sold 58,300 shares of the company's stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $7.42, for a total transaction of $432,586.00. Following the sale, the insider directly owned 236,982 shares in the company, valued at approximately $1,758,406.44. This represents a 19.74% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 1.70% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，內部人士 Kimberly Maersk-Moller 於 11 月 6 日星期四出售了 58,300 股該公司的股票。股票以平均價格 7.42 美元出售，總交易額為 432,586.00 美元。出售後，該內部人士直接持有該公司 236,982 股股票，價值約 1,758,406.44 美元。這代表其持股減少了 19.74%。該交易在向 SEC 提交的文件中披露，相關文件可通過此超鏈接訪問。內部人士持有該公司 1.70% 的股票。</p>
</div><h2>MiMedx Group Trading Up 1.1%</h2>
<div class="lb-trans"><h2>MiMedx Group 股價上漲 1.1%</h2>
</div><p>Shares of MDXG opened at $7.08 on Friday. The business has a 50-day moving average of $7.05 and a 200 day moving average of $6.88. MiMedx Group, Inc has a fifty-two week low of $5.79 and a fifty-two week high of $9.71. The firm has a market cap of $1.05 billion, a P/E ratio of 26.20 and a beta of 1.64. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.95 and a current ratio of 4.41.</p>
<div class="lb-trans"><p>MDXG 的股票在星期五開盤價為 7.08 美元。該公司的 50 日移動平均線為 7.05 美元，200 日移動平均線為 6.88 美元。MiMedx Group, Inc 的 52 周低點為 5.79 美元，52 周高點為 9.71 美元。該公司的市值為 10.5 億美元，市盈率為 26.20，貝塔係數為 1.64。該公司的債務與股本比率為 0.07，速動比率為 3.95，流動比率為 4.41。</p>
</div><p>MiMedx Group (NASDAQ:MDXG - Get Free Report) last released its quarterly earnings data on Monday, November 13th. The company reported ($0.03) EPS for the quarter. The business had revenue of $67.69 million for the quarter. MiMedx Group had a net margin of 10.38% and a return on equity of 27.19%. As a group, research analysts forecast that MiMedx Group, Inc will post 0.3 EPS for the current year.</p>
<div class="lb-trans"><p>MiMedx Group (NASDAQ:MDXG - 獲取免費報告) 最近於 11 月 13 日星期一發布了季度財報。該公司報告本季度每股收益為（0.03）美元。該公司的季度收入為 67.69 百萬美元。MiMedx Group 的淨利潤率為 10.38%，股本回報率為 27.19%。作為一個整體，研究分析師預測 MiMedx Group, Inc 本年度將發佈 0.3 的每股收益。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>A number of equities analysts recently weighed in on the stock. Wall Street Zen raised shares of MiMedx Group from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a report on Sunday, November 2nd. Mizuho lowered their price objective on shares of MiMedx Group from $12.00 to $10.00 and set an &#34;outperform&#34; rating on the stock in a research report on Wednesday, December 17th. Finally, Weiss Ratings reissued a &#34;hold (c)&#34; rating on shares of MiMedx Group in a research report on Monday. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $11.00.</p>
<div class="lb-trans"><p>一些股票分析師最近對該股票進行了評估。華爾街 Zen 在 11 月 2 日星期日的報告中將 MiMedx Group 的股票評級從 “買入” 上調至 “強力買入”。瑞穗證券在 12 月 17 日的研究報告中將 MiMedx Group 的股票目標價從 12.00 美元下調至 10.00 美元，並對該股票給予 “跑贏大盤” 的評級。最後，Weiss Ratings 在週一的研究報告中重新發布了對 MiMedx Group 股票的 “持有（c）” 評級。兩位投資分析師對該股票給予了買入評級，一位給予了持有評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，共識目標價為 11.00 美元。</p>
</div><p><strong>Get Our Latest Report on MDXG</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 MDXG 的最新報告</strong></p>
</div><h2>MiMedx Group Company Profile</h2>
<div class="lb-trans"><h2>MiMedx Group 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company's core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx's product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.</p>
<div class="lb-trans"><p>MiMedx Group, Inc 是一家生物製藥公司，專注於開發、製造和營銷源自人類胎盤組織的再生生物材料產品。該公司的核心使命是利用羊膜和絨毛膜中的細胞外基質和生長因子來支持傷口癒合和外科應用。MiMedx 的產品線利用專有的淨化工藝，旨在保留原生組織特性，同時確保無菌和安全。</p>
</div><p>MiMedx's principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.</p>
<div class="lb-trans"><p>MiMedx 的主要產品包括以 EpiFix® 和 AmnioFix® 等名稱品牌的羊膜/絨毛膜同種異體移植物，適用於急性和慢性傷口的治療，包括糖尿病足潰瘍、靜脈性腿部潰瘍和手術部位修復。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than MiMedx Group</li>
<li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li>
<li>Washington prepares for war</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>The McDonald's Secret</li>
<li>33,000% boom from weird new “AI Fuel?”</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 MiMedx Group</li>
<li>將你的 “死錢” 轉變為每月 306 美元以上（從這個月開始）</li>
<li>華盛頓準備開戰</li>
<li>在 1 月 1 日之前將 1,000 美元投入這隻股票 [不是 NVDA]</li>
<li>麥當勞的秘密</li>
<li>來自奇怪的新 “AI 燃料” 的 33,000% 繁榮？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=MDXG"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MiMedx Group Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 MiMedx Group 嗎？</h2>
</div><p>Before you consider MiMedx Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 MiMedx Group 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買... 而 MiMedx Group 並不在名單上。</p>
</div><p>While MiMedx Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 MiMedx Group 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Harbor Capital Advisors Inc. 減少了其在 MiMedx Group, Inc $MDXG 中的持股